Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation

Synapse

Volumn 61, Issue 3, 2007, Pages 157-165

  Middleton, Lisa S ^a   Crooks, Peter A ^a   Wedlund, Peter J ^a   Cass, Wayne A ^b   Dwoskin, Linda P ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c University of Kentucky   (United States)

Author keywords

DA transporter; In vivo voltammetry; Nicotine; Nicotinic receptors; Nornicotine

Indexed keywords

ACETYLCHOLINE; DOPAMINE TRANSPORTER; MECAMYLAMINE; NICOTINIC RECEPTOR; NORNICOTINE;

AMPEROMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; ELECTROCHEMICAL ANALYSIS; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; POTENTIOMETRY; PRIORITY JOURNAL; RAT; TOBACCO DEPENDENCE;

ACETYLCHOLINE; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INSECTICIDES; MALE; MECAMYLAMINE; METABOLIC CLEARANCE RATE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION; TIME FACTORS; TOBACCO USE DISORDER;

EID: 33846234726     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20351     Document Type: Article

References (44)

1. Bardo MT, Green TA, Crooks PA, Dwoskin LP. 1999. Nornicotine is self-administered intravenously by rats. Psychopharmacology 146:290-296.
2. Corrigall WA, Franklin KBJ, Coen KM, Clarke PBS. 1992. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285-289.
3. Crooks PA, Dwoskin LP. 1997. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 54:743-753.
4. Crooks PA, Li M, Dwoskin LP. 1997. Metabolites of nicotine in rat brain after peripheral nicotine administration. Cotinine, nornicotine, and norcotinine. Drug Metab Dispos 25:47-54.
5. Damaj MI, Fei-Yin M, Dukat M, Glassco W, Glennon RA, Martin BR. 1998. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther 284:1058-1065.
6. Damaj MI, Flood P, Ho KK, May EL, Martin BR. 2005. Effect of dextromethorphan and dextrorphan on nicotine and neuronal nicotinic receptors: In vitro and in vivo selectivity. J Pharmacol Exp Ther 312:780-785.
7. Damsma G, Westerink BH, de Vries JB, Horn AS. 1988. The effect of systemically applied cholinergic drugs on the striatal release of dopamine and its metabolites, as determined by automated brain dialysis in conscious rats. Neurosci Lett 89:349-354.
8. Dwoskin LP, Buxton ST, Jewell AL, Crooks PA. 1993. S(-)-Nornicotine increases dopamine release in a calcium-dependent manner from superfused rat striatal slices. J Neurochem 60:2167-2174.
9. Ghosheh OA, Dwoskin LP, Miller DK, Crooks PA. 2001. Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2′-(14)C]nicotine. Drug Metab Dispos 29:645-651.
10. Green TA, Phillips SB, Crooks PA, Dwoskin LP, Bardo MT. 2000. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats. Psychopharmacology 152:289-294.
11. 3H]dopamine overflow from rat nucleus accumbens slices. Biochem Pharmacol 62:597-1603.
12. Hart C, Ksir C. 1996. Nicotine effects on dopamine clearance in rat nucleus accumbens. J Neurochem 66:216-221.
13. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. 1998. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Ann Rev Pharmacol Toxicol 38:461-499.
14. Janhunen S, Ahtee L. 2004, Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. Eur J Pharmacol 494:167-177.
15. 3H]dopamine release from rat striatal synaptosomes and slices. J Neurochem 70:1069-1076.
16. Kelley AE, Berridge KC. 2002. The neuroscience of natural rewards: Relevance to addictive drugs. J Neurosci 22:3306-3311.
17. Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, Vesell ES. 1990. Disposition of nicotine and eight metabolites in smokers and nonsmokers: Identification in smokers of two metabolites that are longer lived than cotinine. Clin Pharmacol Ther 48:641-651.
18. Levin ED, Petro A, Beatty A. 2005. Olanzapine interactions with nicotine and mecamylamine in rats: Effects on memory function. Neurotoxicol Teratol 27:459-464.
19. Marshall DL, Redfern PH, Wonnacott S. 1997. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats. J Neurochem 68:1511-1519.
20. Martin-Soelch C, Leenders KL, Chevalley AF, Missimer J, Kunig G, Magyar S, Mino A, Schultz W. 2001. Reward mechanisms in the brain and their role in dependence: Evidence from neurophysiological and neuroimaging studies. Brain Res Brain Res Rev 36:139-149.
21. Mathieu-Kia AM, Kellog SH, Butelman ER, Kreek MJ. 2002. Nicotine addiction: Insights from recent animal studies. Psychopharmacology 162:102-118.
22. Meyer EM, Tay ET, Papke RL, Meyers C, Huang GL, de Fiebre CM. 1997. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 768:49-56.
23. Middleton LS, Cass WA, Dwoskin LP. 2004. Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex. J Pharmacol Exp Ther 308:367-377.
24. Miller DK, Wilkins LH, Bardo MT, Crooks PA, Dwoskin LP. 2001. Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism. Psychopharmacology 156:469-476.
25. Murphy SE, Raulinaitis R, Brown KM. 2005. Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 53:1166-1173.
26. Papke RL, Sanberg PR, Shytle RD. 2001. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther 297:646-656.
27. Papke RL, Buhr JD, Francis MM, Choi K, Thinschmid JS, Horenstein NA. 2005. The effects of subunit composition on the inhibition of nicotinic receptors by the amphipathic blocker 2,2,6,6-tetramethylpiperidin-4-yl- heptanoate. Mol Pharmacol 67:1977-1990.
28. Paxinos G, Watson C. 1986. The rat brain atlas in stereotaxic coordinates. San Diego, CA: Academic Press.
29. Pomerleau CS, Pomerleau OF. 1992. Euphoriant effects of nicotine in smokers. Psychopharmacology 108:460-465.
30. 3H](-)-nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacology 27:235-241.
31. 3H]MK801 binding to the N-methyl-D-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites. J Pharmacol Exp Ther 247:1025-1031.
32. Sabeti J, Adams CE, Burmeister J, Gerhardt GA, Zahniser NR. 2002. Kinetic analysis of striatal clearance of exogenous dopamine recorded by chronoamperometry in freely-moving rats. J Neurosci Methods 121:41-52.
33. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP. 2005. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62:649-659.
34. Shargel L, Wu-Pong S, Yu ABC. 2005, Applied biopharmaceutics and pharmacokinetics. New York, NY: McGraw-Hill Medical.
35. 3H-(1-[1-(2-thienyl)cyclohexyl]-piperidine) binding in rat hippocampus. Synapse 3:129-135.
36. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG. 1997. Multiple ionic conductances of the human dopamine transporter: The actions of dopamine and psychostimulants. J Neurosci 17:960-974.
37. Stairs DJ, Neugebauer NM, Wei X, Boustany C, Hojahmat M, Cassis LA, Crooks PA, Dwoskin LP, Bardo MT. 2006. Effects of nornicotine enantiomers on intravenous S(-)-nicotine self-administration and cardiovascular function in rats. Psychopharmacology [Epub ahead of Print]. PMID: 16905316.
38. Swango JH, Bhatti BS, Qureshi MM, Crooks PA. 1999. A novel enantioselective synthesis of (S)-(-)- and (R)-(+)-nornicotine via alkylation of a chiral 2-hydroxy-3-pinanone ketimine template. Chirality 11:316-318.
39. 3H]dopamine. J Pharmacol Exp Ther 283:778-787.
40. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A. 1992. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: Role of glutamic acid. Neurochem Res 17:265-271.
41. Valette H, Bottlaender M, Dollé F, Coulon C, Ottaviani M, Syrota A. 2003. Long lasting occupancy of central nicotine acetylcholine receptors after smoking: A PET study in monkeys. J Neurochem 84:105-111.
42. Vezina P, Blanc G, Glowinski J, Tassin JP. 1992. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: Effects of acute and repeated injections. J Pharmacol Exp Ther 261:484-490.
43. Xu R, Dwoskin LP, Grinevich VP, Deaciuc G, Crooks PA. 2001. Neuronal nicotinic acetylcholine receptor binding affinities of boron-containing nicotine analogues. Bioorg Med Chem Lett 11:1245-1248.
44. Zahniser NR, Larson GA, Gerhardt GA, 1999. In vivo dopamine clearance rate in rat striatum: Regulation by extracellular dopamine concentration and dopamine transporter inhibitors. J Pharmacol Exp Ther 289:266-277.